Latest Thrombus Stories

NATICK, Mass., Nov. 16, 2011 /PRNewswire/ -- Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin America. The novel device is designed for use in patients in atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. The WATCHMAN LAA Closure Device is intended to prevent embolization of thrombi that may form in the LAA, thereby...

A targeted, nanoparticle gelatin-based clot-busting treatment dissolved significantly more blood clots than a currently used drug in an animal study of acute coronary syndrome presented at the American Heart Association's Scientific Sessions 2011. The new drug-delivery system used gelatin to deactivate the clot-busting drug tissue plasminogen activator, or tPA, to treat acute coronary syndrome. Soundwaves were then used to reactivate tPA once it reached the blood clot. It is considered a...

Ennis & Ennis, P.A. explains the findings of another recent study revealing the significant risk of developing dangerous blood blots associated with birth control pills such as Yaz and Yasmin. (PRWEB) November 09, 2011 The Canadian Medical Association Journal released a study of 330,000 Israeli women indicating that blood clots were more likely for those who were taking Yaz and Yasmin, which are birth control pills that contain the synthetic hormone drospirenone, reported attorney...

(Ivanhoe Newswire) – Drospirenone-containing oral birth control pills are linked to a significantly higher risk of blood clots, both deep vein thrombosis and pulmonary embolism, according to this study. All oral contraceptives are associated with a higher risk of blood clots, but there is conflicting information about the risk of adverse events with drospirenone. Many previous studies have evaluated risks of second- and third-generation contraceptives, which both contain derivatives of...

The use of drospirenone-containing oral birth control pills is linked to a significantly higher risk of blood clots, both deep vein thrombosis and pulmonary embolism, according to an article in the Canadian Medical Association Journal. All oral contraceptives are associated with a higher risk of blood clots, but there is conflicting information about the risk of adverse events with drospirenone. Many previous studies have evaluated risks of second- and third-generation contraceptives,...

SILVER SPRING, Md., Nov. 4, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation). (Logo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20090824/FDALOGO</font>) Atrial fibrillation occurs in more than 2 million Americans and is one of the most common types of abnormal...

Research at Loyola University Chicago Stritch School of Medicine could help lead to new ways to prevent coronary arteries from reclogging after balloon angioplasties. The latest in a series of studies in this effort is published online ahead of print in Arteriosclerosis, Thrombosis and Vascular Biology, a journal of the American Heart Association. Senior author is Allen M. Samarel, MD, and first author is Yevgeniya E. Koshman, PhD. In an angioplasty, a tiny balloon is inflated to open a...

    * Medical and patient communities call on national policymakers in Latin America to take urgent action against preventable strokes that strike millions of people with atrial fibrillation (AF) each year     * AF increases the risk of stroke fivefold and is responsible for one in five of all ischemic strokes caused by a blood clot blocking a blood vessel in the brain 1,2,3,4     * Millions of people in Latin America suffer from AF           o In Brazil, there are...

Considerable regional differences exist in the treatment of patients with acute cerebral infarction. This is the finding presented by Erwin Stolz and his co-authors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2011; 108[36]: 607). The prognosis for patients with stroke largely depends on a rapid, standardized first response. Across the German federal state of Hesse, there are great differences in the time interval between symptom onset and admission to...

MOUNTAIN VIEW, Calif., Sept. 8, 2011 /PRNewswire/ -- Concentric Medical, Inc., a global leader in acute ischemic stroke intervention, today announced completion of enrollment of the TREVO Study. The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first evaluation of Stentriever(TM) technology in a European, multicenter, prospective clinical trial. The TREVO Study was designed to assess the ability of the Trevo® System to remove...